Figure 2.
MC and impending or established secondary GF stratified based on day 0 alemtuzumab levels. (A) Cumulative incidence of MC, defined as donor chimerism <95%. (B) Cumulative incidence of impending or established secondary GF. Stratification using the first quartile day 0 alemtuzumab levels (level ≤ 0.32 μg/mL). D0, day 0.

MC and impending or established secondary GF stratified based on day 0 alemtuzumab levels. (A) Cumulative incidence of MC, defined as donor chimerism <95%. (B) Cumulative incidence of impending or established secondary GF. Stratification using the first quartile day 0 alemtuzumab levels (level ≤ 0.32 μg/mL). D0, day 0.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal